Lipoprotein-Associated Phospholipase A2 – Pathophysiological Role and Clinical Significance as a Cardiovascular Biomarker

Abstract

Within the last decade, a broad range of biomarkers associated with an increased risk for death and cardiovascular/cerebrovascular endpoints have been identified. Epidemiological studies clearly indicate that lipoprotein-associated phospholipase A Lp-PLA has the potential to become clinically useful emerging biomarker in the true sense, linking plaque biology with cardiovascular/cerebrovascular event rate. Lipoprotein-associated phospholipase A is a specific vascular inflammatory marker, a risk factor, a prognostic biomarker, and also a therapeutic target. This chapter will summarize our current knowledge on Lp-PLA with emphasis on its potential pathophysiological mechanisms of action and on clinical relevance as cardiovascular/ cerebrovascular biomarker. This chapter gives comprehensive, systematic review of studies assessing the significance of Lp-PLA in cardiovascular/cerebrovascular diseases with emphasis on clinical benefit of pharmacologic inhibition of Lp-PLA .

Phospholipase enzymes as potential biomarker for SARS CoV-2 virus

“…It had been evidenced that LpPLA2 level upregulation is mainly found in nonhospitalized covid 19 patients. This abnormal increase LpPLA2 was observed in covid 19 re-positive patients as well [58], [59], [60]. Those patients are not showed promising symptoms of pneumonia, however sometimes they first experienced cardiovascular symptoms [61].…”